

**ProteoTech to Present at The 10th International Conference
on Alzheimer's and Parkinson's Disease
Barcelona, Spain, March 9-13, 2011**

Kirkland, WA, March 5, 2011 – ProteoTech, Inc. announced today that Dr. Luke Esposito, Director of Neuroscience Research will present at the 10th International Conference on Alzheimer's and Parkinson's Disease to be held in Barcelona, Spain, March 9-13, 2011. Dr. Esposito will present on Saturday, March 12 during the "Drug Discovery & Development: Movement Disorders" Symposium. Dr. Esposito's presentation is entitled:

"SynuclelTM: A Novel Small Molecule that Effectively Reduces Alpha-Synuclein Aggregation and Improves Motor Dysfunction as a Potential Parkinson's disease-Modifying Therapeutic."

SynuclelTM is a novel small molecule developed by ProteoTech that is postulated to be a disease-modifying treatment for Parkinson's disease and related disorders.

About ProteoTech: ProteoTech is a private drug development company located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides *SynuclelTM* in late stage pre-clinical development for the treatment of Parkinson's disease, the Company is developing EXEBRYL-1[®] for the treatment of Alzheimer's disease, SystebrylTM for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called *PeptiClereTM* for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.